Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clinical stage biopharmaceutical company Autolus Therapeutics has reported a $37.3 million net income loss attributable to ordinary shareholders in its third quarter financial results.
The loss was higher compared to $27.2 million for the third quarter in 2019, but the company said it has sufficient cash to fund operations into 2022.
Autolus, which is a portfolio firm of AIM-listed healthcare company Syncona, is developing next-generation programmed T cell therapies. It saw its research expenses increase by $8.4 million to $33.5 million in the third quarter compared to the same period in the previous year.
Its cash and equivalents as of at September 30 2020 totalled $177.7 million compared with $212.0 million at June 30, 2020. The basic and diluted net loss per ordinary share for the third quarter 2020 totalled $0.72 compared to a loss of $0.61 for the same period in 2019.
At 2:33pm: (LON:SYNC) Syncona Limited share price was +3.5p at 249.5p